As the number of biologics facing patent expiration in the US continues to rise, the market is further opening up to biosimilar manufacturers. George I'ons offers some pointers on how to secure an attractive market share during this time.
George I’ons
Advertisement
George I’ons is head of Product Strategy and Insights, Owen Mumford Pharmaceutical Services.
Articles by George I’ons
Advertisement
Latest Updated Articles
- How Biosimilar Manufacturers Can Get the Most Out of the "Patent Cliff"
Published: May 21st 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
2
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
3
Is FDA Streamlining Regulations in the Biosimilar Space?
4
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
5
